Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a report released on Wednesday.

Several other equities research analysts have also commented on the company. UBS Group upped their target price on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. JPMorgan Chase & Co. raised their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. Finally, Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a report on Wednesday. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Teva Pharmaceutical Industries Trading Up 1.5 %

Shares of TEVA traded up $0.32 during trading hours on Wednesday, hitting $21.20. 23,678,977 shares of the stock were exchanged, compared to its average volume of 9,410,627. The company has a debt-to-equity ratio of 2.57, a current ratio of 0.89 and a quick ratio of 0.61. The firm has a market capitalization of $24.02 billion, a P/E ratio of -24.94, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. The business has a 50-day moving average of $17.54 and a 200-day moving average of $17.43. Teva Pharmaceutical Industries has a fifty-two week low of $10.13 and a fifty-two week high of $21.98.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the transaction, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently made changes to their positions in the company. UMB Bank n.a. boosted its stake in shares of Teva Pharmaceutical Industries by 555.6% in the 3rd quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the last quarter. Smithfield Trust Co lifted its holdings in Teva Pharmaceutical Industries by 55.7% during the third quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after acquiring an additional 980 shares during the period. Wilmington Savings Fund Society FSB bought a new stake in Teva Pharmaceutical Industries during the third quarter worth $50,000. Claro Advisors LLC purchased a new position in Teva Pharmaceutical Industries in the third quarter worth $52,000. Finally, Venturi Wealth Management LLC bought a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at $60,000. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.